Cipla’s affiliate enters into strategic partnership with SIGA Technologies

23 Mar 2021 Evaluate

Cipla Therapeutics, a division of Cipla USA, Inc., an affiliate of Cipla and SIGA Technologies, Inc. (SIGA) have entered into a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against biothreats. The strategic collaboration between Cipla and SIGA will provide the Biomedical Advanced Research and Development Authority (BARDA), a U.S. Department of Health and Human Services (HHS) department, with solutions for its biothreat and public health needs.

The World Health Organization has declared that anti-microbial resistance (AMR) one of the top 10 global public health threats facing humanity 2 which puts at risk the effective prevention and treatment of a wide range of infections. According to the AMR Industry Alliance, a global AMR private sector coalition, AMR is the ability of a microorganism (such as bacteria, viruses, and some parasites) to stop an antimicrobial (such as antibiotics, antivirals and antimalarials) from working against it. It is an increasingly significant threat to global public health which is present in every country around the world and infections caused by drug-resistant bacteria can cause death.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1313.00 -1.85 (-0.14%)
27-Jan-2026 15:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1638.70
Dr. Reddys Lab 1240.85
Cipla 1313.00
Zydus Lifesciences 893.00
Lupin 2147.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×